{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:38:40Z","timestamp":1793324320567,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T00:00:00Z","timestamp":1745712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T00:00:00Z","timestamp":1745712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>To evaluate and compare cancer detection rates (CDRs) of transition zone (TZ) lesions upgraded from PI-RADSv2.1 score 2 to 3 (\u201c2\u2009+\u20091\u201d) or from 3 to 4 (\u201c3\u2009+\u20091\u201d) using DWI and assess their clinical impact.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and methods<\/jats:title>\n            <jats:p>A systematic literature search was performed in Embase, Medline, and Web of Science for studies assessing TZ lesions with DWI in PI-RADSv2.1, with histology-confirmed grade group \u2265\u20092 cancer (GG\u2009\u2265\u20092) as the primary outcome. Risk of bias was evaluated using QUADAS-2. Pooled sensitivity, specificity, CDRs, and odds ratios (ORs) were estimated at the lesion level using a bivariate binomial random-effects model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Eight studies with 1535 TZ lesions were included. GG\u2009\u2265\u20092 CDRs for PI-RADS scores of 1, 2, 2\u2009+\u20091, 3, 3\u2009+\u20091, 4, and 5 were 2% (95%CI: 0%\u201312%), 6% (4%\u201310%), 13% (6%\u201323%), 19% (15%\u201325%), 37% (24%\u201352%), 49% (32%\u201367%), and 73% (66%\u201379%), respectively. Scores of 2\u2009+\u20091 had higher GG\u2009\u2265\u20092 CDRs than 2 (OR 3.37 (1.53\u20137.44), <jats:italic>p<\/jats:italic>\u2009=\u20090.003) but were similar to 3 (OR 0.80 (0.44\u20131.45), <jats:italic>p<\/jats:italic>\u2009=\u20090.46). Scores of 3\u2009+\u20091 had higher GG\u2009\u2265\u20092 CDRs than 3 (OR 2.67 (1.27\u20135.59), <jats:italic>p<\/jats:italic>\u2009=\u20090.009) but were similar to 4 (OR 0.68 (0.33\u20131.44), <jats:italic>p<\/jats:italic>\u2009=\u20090.32). False-positive rates remained substantial (\u2265\u20092\u2009+\u20091: 69% (55%\u201380%); \u2265\u20093: 54% (46%\u201362%)).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The risk of having significant prostate cancer in \u201c2\u2009+\u20091\u201d and \u201c3\u2009+\u20091\u201d TZ lesions, with an upgrading based on DWI images, is appropriately categorized within the PI-RADS v2.1 scoring system, as shown by this meta-analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Key Points<\/jats:title>\n            <jats:p>\n              <jats:bold>\n                <jats:italic>Question<\/jats:italic>\n              <\/jats:bold>\n              <jats:italic>PI-RADS v2.1 incorporates rules allowing scores of some transition zone (TZ) lesions to be increased. Literature on the clinical impact of these rules is scarce.<\/jats:italic>\n            <\/jats:p>\n            <jats:p>\n              <jats:bold>\n                <jats:italic>Findings<\/jats:italic>\n              <\/jats:bold>\n              <jats:italic>For TZ lesions upgraded with DWI:<\/jats:italic> \u201c<jats:italic>2<\/jats:italic>\u2009<jats:italic>+<\/jats:italic>\u2009<jats:italic>1<\/jats:italic>\u201d <jats:italic>lesions show a cancer detection rate (CDR) of 13%, and<\/jats:italic> \u201c<jats:italic>3<\/jats:italic>\u2009<jats:italic>+<\/jats:italic>\u2009<jats:italic>1<\/jats:italic>\u201d <jats:italic>lesions show a CDR of 37%.<\/jats:italic>\n            <\/jats:p>\n            <jats:p>\n              <jats:bold>\n                <jats:italic>Clinical relevance<\/jats:italic>\n              <\/jats:bold>\n              <jats:italic> Upgraded TZ lesions may impact individualized biopsy-decisions, especially as<\/jats:italic> \u201c<jats:italic>3<\/jats:italic>\u2009<jats:italic>+<\/jats:italic>\u2009<jats:italic>1<\/jats:italic>\u201d <jats:italic>lesions harbor significant disease in 2-out-of-5 patients. Still, the high rate of grade group<\/jats:italic>\u2009<jats:italic>=<\/jats:italic>\u2009<jats:italic>1 and benign findings in these sub-categories emphasizes the need for strategies to minimize overdiagnosis.<\/jats:italic>\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1007\/s00330-025-11618-w","type":"journal-article","created":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T09:36:43Z","timestamp":1745746603000},"page":"6454-6465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Detection rates for prostate cancer using PI-RADS 2.1 upgrading rules in transition zone lesions align with risk assessment categories: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3752-1315","authenticated-orcid":false,"given":"Georgios","family":"Agrotis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Pais","family":"Pooch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostas","family":"Marsitopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Vlychou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Benndorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina G. H.","family":"Beets-Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo G.","family":"Schoots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,27]]},"reference":[{"key":"11618_CR1","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA et al (2019) Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 76:340\u2013351. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.033","journal-title":"Eur Urol"},{"key":"11618_CR2","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"11618_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"PF Whiting","year":"2011","unstructured":"Whiting PF (2011) QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529. https:\/\/doi.org\/10.7326\/0003-4819-155-8-201110180-00009","journal-title":"Ann Intern Med"},{"key":"11618_CR4","doi-asserted-by":"crossref","unstructured":"Deeks JJ, Bossuyt PM, Leeflang MM, Takwoingi Y (2023) Presenting findings. In: Deeks JJ, Bossuyt PM, Leeflang MM, Takwoingi Y (eds) Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy, 1st edn. Wiley, 327\u2013348","DOI":"10.1002\/9781119756194.ch11"},{"key":"11618_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v083.i01","volume":"83","author":"J Guo","year":"2018","unstructured":"Guo J, Riebler A (2018) meta4diag: Bayesian bivariate meta-analysis of diagnostic test studies for routine practice. J Stat Softw 83:1\u201331. https:\/\/doi.org\/10.18637\/jss.v083.i01","journal-title":"J Stat Softw"},{"key":"11618_CR6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G (2019) How to perform a meta-analysis with R: a practical tutorial. BMJ Ment Health 22:153\u2013160. https:\/\/doi.org\/10.1136\/ebmental-2019-300117","journal-title":"BMJ Ment Health"},{"key":"11618_CR7","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.21873\/invivo.12963","volume":"36","author":"H Engel","year":"2022","unstructured":"Engel H, Oerther B, Reisert M et al (2022) Quantitative analysis of diffusion weighted imaging may improve risk stratification of prostatic transition zone lesions. In Vivo 36:2323\u20132331. https:\/\/doi.org\/10.21873\/invivo.12963","journal-title":"Vivo"},{"key":"11618_CR8","doi-asserted-by":"publisher","unstructured":"Asai S, Kobayashi M, Fukuda S et al (2024) Significance of atypical nodules upgraded to category 3 in Prostate Imaging Reporting and Data System Version 2.1 for prostate cancer diagnosis. Int J of Urol 15421. https:\/\/doi.org\/10.1111\/iju.15421","DOI":"10.1111\/iju.15421"},{"key":"11618_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-72544-z","volume":"10","author":"MM Rudolph","year":"2020","unstructured":"Rudolph MM, Baur ADJ, Cash H et al (2020) Diagnostic performance of PI-RADS version 2.1 compared to version 2.0 for detection of peripheral and transition zone prostate cancer. Sci Rep 10:15982. https:\/\/doi.org\/10.1038\/s41598-020-72544-z","journal-title":"Sci Rep"},{"key":"11618_CR10","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2214\/AJR.20.23932","volume":"216","author":"CS Lim","year":"2021","unstructured":"Lim CS, Abreu-Gomez J, Carrion I, Schieda N (2021) Prevalence of prostate cancer in PI-RADS version 2.1 transition zone atypical nodules upgraded by abnormal DWI: correlation with MRI-directed TRUS-guided targeted biopsy. AJR Am J Roentgenol 216:683\u2013690. https:\/\/doi.org\/10.2214\/AJR.20.23932","journal-title":"Am J Roentgenol"},{"key":"11618_CR11","doi-asserted-by":"publisher","first-page":"e221309","DOI":"10.1148\/radiol.221309","volume":"307","author":"EC Yilmaz","year":"2023","unstructured":"Yilmaz EC, Shih JH, Belue MJ et al (2023) Prospective evaluation of PI-RADS version 2.1 for prostate cancer detection and investigation of multiparametric MRI-derived markers. Radiology 307:e221309. https:\/\/doi.org\/10.1148\/radiol.221309","journal-title":"Radiology"},{"key":"11618_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2214\/AJR.20.24370","volume":"217","author":"DN Costa","year":"2021","unstructured":"Costa DN, Jia L, Subramanian N et al (2021) Prospective PI-RADS v2.1 atypical benign prostatic hyperplasia nodules with marked restricted diffusion: detection of clinically significant prostate cancer on multiparametric MRI. AJR Am J Roentgenol 217:395\u2013403. https:\/\/doi.org\/10.2214\/AJR.20.24370","journal-title":"Am J Roentgenol"},{"key":"11618_CR13","doi-asserted-by":"publisher","unstructured":"De Oliveira Correia ET, Purysko AS, Paranhos BM et al (2024) PI-RADS upgrading rules: impact on prostate cancer detection and biopsy avoidance of MRI-directed diagnostic pathways. AJR Am J Roentgenol 23.30611. https:\/\/doi.org\/10.2214\/AJR.23.30611","DOI":"10.2214\/AJR.23.30611"},{"key":"11618_CR14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/jmri.27080","volume":"52","author":"J Byun","year":"2020","unstructured":"Byun J, Park KJ, Kim M-H, Kim JK (2020) Direct comparison of PI-RADS version 2 and 2.1 in transition zone lesions for detection of prostate cancer: preliminary experience. J Magn Reson Imaging 52:577\u2013586. https:\/\/doi.org\/10.1002\/jmri.27080","journal-title":"J Magn Reson Imaging"},{"key":"11618_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1148\/radiol.2016161124","volume":"283","author":"AB Rosenkrantz","year":"2017","unstructured":"Rosenkrantz AB, Babb JS, Taneja SS, Ream JM (2017) Proposed adjustments to PI-RADS version 2 decision rules: impact on prostate cancer detection. Radiology 283:119\u2013129. https:\/\/doi.org\/10.1148\/radiol.2016161124","journal-title":"Radiology"},{"key":"11618_CR16","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1148\/radiol.2018170425","volume":"288","author":"JN Thai","year":"2018","unstructured":"Thai JN, Narayanan HA, George AK et al (2018) Validation of PI-RADS version 2 in transition zone lesions for the detection of prostate cancer. Radiology 288:485\u2013491. https:\/\/doi.org\/10.1148\/radiol.2018170425","journal-title":"Radiology"},{"key":"11618_CR17","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41391-021-00417-1","volume":"25","author":"B Oerther","year":"2022","unstructured":"Oerther B, Engel H, Bamberg F et al (2022) Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level. Prostate Cancer Prostatic Dis 25:256\u2013263. https:\/\/doi.org\/10.1038\/s41391-021-00417-1","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"11618_CR18","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/jmri.27191","volume":"53","author":"N Schieda","year":"2021","unstructured":"Schieda N, Lim CS, Zabihollahy F et al (2021) Quantitative prostate MRI. Magn Reson Imaging 53:1632\u20131645. https:\/\/doi.org\/10.1002\/jmri.27191","journal-title":"Magn Reson Imaging"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11618-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-025-11618-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11618-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T10:03:33Z","timestamp":1757498613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-025-11618-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,27]]},"references-count":18,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["11618"],"URL":"https:\/\/doi.org\/10.1007\/s00330-025-11618-w","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,27]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Prof. Ivo G. Schoots.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"R.G.H.B.T. is a member of the Scientific Editorial Board for European Radiology (Section: Oncology). As such they did not participate in the selection nor review processes for this article. The remaining authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"One of the authors has significant statistical expertise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was not required for this study because it is a systematic review.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was not required because it is a systematic review.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No overlap of cohorts.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}